CL2008002027A1 - Compuestos derivados de 16alfa-fluoro-estra-1,3,5(10)-trieno obeta-sustituido;composicion farmaceutica; y uso de los compuestos para tratar enfermedades inducidas por la deficiencia de estrogeno, infertilidad, sintomas peri y posmenopausicos, artritis reumatica, enfermedades intestinales inflamatorias, entre otras. - Google Patents

Compuestos derivados de 16alfa-fluoro-estra-1,3,5(10)-trieno obeta-sustituido;composicion farmaceutica; y uso de los compuestos para tratar enfermedades inducidas por la deficiencia de estrogeno, infertilidad, sintomas peri y posmenopausicos, artritis reumatica, enfermedades intestinales inflamatorias, entre otras.

Info

Publication number
CL2008002027A1
CL2008002027A1 CL2008002027A CL2008002027A CL2008002027A1 CL 2008002027 A1 CL2008002027 A1 CL 2008002027A1 CL 2008002027 A CL2008002027 A CL 2008002027A CL 2008002027 A CL2008002027 A CL 2008002027A CL 2008002027 A1 CL2008002027 A1 CL 2008002027A1
Authority
CL
Chile
Prior art keywords
compounds
estra
substituted
obeta
16alpha
Prior art date
Application number
CL2008002027A
Other languages
English (en)
Inventor
Muhn Peter
Fritzemeier Karl-Heinrich
Prelle Katja
Pete Olaf
Bräuer Nico
Thieme Ina
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CL2008002027A1 publication Critical patent/CL2008002027A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta

Abstract

COMPUESTOS DERIVADOS DE ESTRA-1,3,5(10)-TRIENO 8B-SUSTITUIDOS DE FORMA GENERAL I (I), DONDE R3, R8, R13, R16, R17 Y R17 TIENEN EL SIGNIFICADO DADO EN LA MEMORIA DESCRIPTIVA Y PLIEGO; SU USO COMO INGREDIENTES FARMACÉUTICOS ACTIVOS QUE TIENEN UNA MAYOR AFINIDAD IN VITRO POR PREPARACIONES DE RECEPTORES DE ESTROGENO DE PRÓSTATA DE RATA QUE POR PREPARACIONES DE RECEPTORES DE ESTROGENO DE ÚTERO DE RATA, Y QUE PRESENTAN UNA ACCIÓN PREFERENCIAL IN VIVO EN EL OVARIO EN COMPARACIÓN CON EL ÚTERO, SU USO TERAPÉUTICO. Y COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS.
CL2008002027A 2007-07-12 2008-07-11 Compuestos derivados de 16alfa-fluoro-estra-1,3,5(10)-trieno obeta-sustituido;composicion farmaceutica; y uso de los compuestos para tratar enfermedades inducidas por la deficiencia de estrogeno, infertilidad, sintomas peri y posmenopausicos, artritis reumatica, enfermedades intestinales inflamatorias, entre otras. CL2008002027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07075600A EP2014672A1 (en) 2007-07-12 2007-07-12 8-beta-substituted estratrienes as selectively active estrogens

Publications (1)

Publication Number Publication Date
CL2008002027A1 true CL2008002027A1 (es) 2009-01-16

Family

ID=38657613

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002027A CL2008002027A1 (es) 2007-07-12 2008-07-11 Compuestos derivados de 16alfa-fluoro-estra-1,3,5(10)-trieno obeta-sustituido;composicion farmaceutica; y uso de los compuestos para tratar enfermedades inducidas por la deficiencia de estrogeno, infertilidad, sintomas peri y posmenopausicos, artritis reumatica, enfermedades intestinales inflamatorias, entre otras.

Country Status (34)

Country Link
US (1) US20090029957A1 (es)
EP (2) EP2014672A1 (es)
JP (1) JP2010533152A (es)
KR (1) KR20100037593A (es)
CN (1) CN101687902B (es)
AR (1) AR067507A1 (es)
AU (1) AU2008274198A1 (es)
BR (1) BRPI0814207A2 (es)
CA (1) CA2692727A1 (es)
CL (1) CL2008002027A1 (es)
CO (1) CO6270230A2 (es)
CR (1) CR11211A (es)
CU (1) CU23885B1 (es)
CY (1) CY1113351T1 (es)
DK (1) DK2176282T3 (es)
DO (1) DOP2010000017A (es)
EA (1) EA017124B1 (es)
EC (1) ECSP109872A (es)
ES (1) ES2393942T3 (es)
HN (1) HN2010000081A (es)
HR (1) HRP20120952T1 (es)
MA (1) MA31565B1 (es)
NZ (1) NZ582490A (es)
PA (1) PA8789401A1 (es)
PE (1) PE20090825A1 (es)
PL (1) PL2176282T3 (es)
PT (1) PT2176282E (es)
RS (1) RS52541B (es)
SI (1) SI2176282T1 (es)
TN (1) TN2010000007A1 (es)
TW (1) TW200911824A (es)
UA (1) UA99918C2 (es)
UY (1) UY31220A1 (es)
WO (1) WO2009007454A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830984C (en) * 2011-03-25 2020-02-11 Universite Laval Inhibitors of 17.beta.-hsd1, 17.beta.-hsd3 and 17.beta.-hsd10.
US10744439B2 (en) * 2016-06-24 2020-08-18 K&N Engineering, Inc. Compound air filter and method of removing airborne molecular contaminants and volatile organic compounds therefrom
USD905747S1 (en) 2018-04-09 2020-12-22 Mitsubishi Electric Corporation Display screen with animated graphical user interface

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
AU2001258341B2 (en) * 2000-04-12 2007-03-15 Schering Aktiengesellschaft 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens

Also Published As

Publication number Publication date
EA201000097A1 (ru) 2010-08-30
PA8789401A1 (es) 2009-04-23
TW200911824A (en) 2009-03-16
SI2176282T1 (sl) 2013-02-28
CN101687902B (zh) 2013-07-24
WO2009007454A2 (en) 2009-01-15
EA017124B1 (ru) 2012-10-30
EP2176282B1 (en) 2012-08-22
HRP20120952T1 (hr) 2012-12-31
CA2692727A1 (en) 2009-01-15
NZ582490A (en) 2012-03-30
WO2009007454A3 (en) 2009-03-05
CO6270230A2 (es) 2011-04-20
DK2176282T3 (da) 2012-12-03
JP2010533152A (ja) 2010-10-21
RS52541B (en) 2013-04-30
AR067507A1 (es) 2009-10-14
DOP2010000017A (es) 2010-01-31
CU23885B1 (es) 2013-04-19
PE20090825A1 (es) 2009-07-25
ES2393942T3 (es) 2013-01-02
AU2008274198A1 (en) 2009-01-15
EP2014672A1 (en) 2009-01-14
PL2176282T3 (pl) 2013-06-28
MA31565B1 (fr) 2010-08-02
CR11211A (es) 2010-04-27
KR20100037593A (ko) 2010-04-09
TN2010000007A1 (en) 2011-09-26
BRPI0814207A2 (pt) 2015-01-27
CY1113351T1 (el) 2016-06-22
UY31220A1 (es) 2009-03-02
PT2176282E (pt) 2012-11-30
ECSP109872A (es) 2010-02-26
HN2010000081A (es) 2013-07-01
EP2176282A2 (en) 2010-04-21
CN101687902A (zh) 2010-03-31
US20090029957A1 (en) 2009-01-29
CU20100008A7 (es) 2011-05-27
UA99918C2 (ru) 2012-10-25

Similar Documents

Publication Publication Date Title
CL2009000498A1 (es) Compuestos derivados de benzo [f][1,7]naftiridin sustituidos, moduladores de receptor toll; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedad infecciosa, inflamatoria, dermatologica, respiratoria o inmune.
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
ES2525497T3 (es) Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
CO6480948A2 (es) Composición farmacéutica para la anticoncepción de emergencia
BR112015012840A2 (pt) composto, composição, e, uso de um composto ou um sal, solvato, éster ou pró-droga farmaceuticamente aceitável do mesmo
PE20061091A1 (es) FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRANDINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
UY32591A (es) Inhibidores ciclicos de 11beta-hidroxiesteroide deshidrogenasa 1
CR11857A (es) Compuestos pirazolicos 436
ECSP12012355A (es) Derivados de 6,7-dihidro-5h-benzo[7]anulenos, métodos para su preparación, preparaciones farmacéuticas que los contienen y su uso para la preparación de medicamentos
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
CU20120012A7 (es) Derivados de 17-hidroxi-17-pentafluoretil-estra-4,9(10)-dien-11-arilo
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
MX2011011126A (es) Composiciones y metodos para tratar quemaduras.
ECSP055530A (es) Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
CL2008002027A1 (es) Compuestos derivados de 16alfa-fluoro-estra-1,3,5(10)-trieno obeta-sustituido;composicion farmaceutica; y uso de los compuestos para tratar enfermedades inducidas por la deficiencia de estrogeno, infertilidad, sintomas peri y posmenopausicos, artritis reumatica, enfermedades intestinales inflamatorias, entre otras.
UY28911A1 (es) Profármacos de esteroides con acción androgénica
GT200600335A (es) Moduladores del receptor de progesterona cianopirrol-fenil amida y usos de los mismos
ECSP078043A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
UY32005A (es) Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a
CL2008002289A1 (es) Compuestos derivados de n-heteroaril-carboxamidas triciclicas; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar dolor, inflamacion, trastornos metabolicos, trastornos urologicos, entre otros.
CR9981A (es) Prodrogas de sustancias erb-selectivas, procesos para su preparacion y composiciones farmaceuticas que comprenden estos productos
UY31212A1 (es) Composición farmacéutica que comprende la combinación de un agente derivado benzisoxazolico y un agente benzodiazepinico